What I found interesting is this blurb in the prospectus: "It is currently expected that the BETonMACE trial will be completed and top line results will be available in mid-calendar year 2019." Does that mean by July end?  I had been assuming end August, as checking up on 2400 very sick patients can't be easy...but this "mid calendar" is heartening.  Since it is now 1.5 months since the last announcement, that suggests the last rounds are going swimmingly fast!

In addition, the prospectus says: "The Corporation is examining both non-dilutive and dilutive financing arrangements, with a preference for non-dilutive alternatives."  Any thoughts what non-dilutive alternatives RVX is thinking of?